补肾益气活血法对老年2型糖尿病颈动脉硬化及内皮功能影响的研究
|
摘要
目的:观察补肾益气活血法对老年2型糖尿病颈动脉硬化及血管内皮功能的影响，并通过实验研究探讨该治法改善血管内皮功能、减轻动脉硬化的机制。
方法:1.临床研究选择符合老年2型糖尿病西医诊断标准及中医肾虚血瘀证辨证分型标准，合并有颈动脉粥样斑块形成者61人；随机分对照组（30人）、试验组（31人），对照组予以常规降糖治疗，试验组在此基础上加服补肾益气活血方，治疗8周，观察治疗前后血糖、糖化血红蛋白、中医症候疗效变化，并对血脂、内皮素（ET)和一氧化氮(NO)、血栓素B2(TXB2)和6-酮-前列环素(6-Keto-PGF1α)、颈动脉内膜中层厚度、动脉斑块面积等相关指标进行比较。2.试验研究将WISTAR雄性大鼠随机分为3组，分别为空白组对照组（以下简称空白组）、模型对照组（以下简称模型组）和补肾益气活血方试验组（以下简称试验组），每组各10只。以高脂高糖饲料喂养4周后造模，造模后试验组大鼠灌服补肾益气活血方中药混悬液，连续灌胃6周。6周后观察各组大鼠的体重、血糖、血脂、及ET、N0，TXB2、6-Keto-PGF1α、AGEs、eNOS，并取心肌、主动脉做病理切片进行显微镜下观察。
结果:临床研究显示试验组患者各项中医临床症状改善明显，空腹血糖、餐后2小时血糖和糖化血红蛋白均较治疗前降低，试验组治疗后糖化血红蛋白下降较对照组明显；试验组可显著改善患者内皮功能，疗效优于对照组；试验组可明显降低患者甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平，疗效优于对照组；试验组在降低颈动脉内膜中层厚度，减少颈动脉斑块面积方面优于对照组。
实验研究显示试验组可改善2型糖尿病模型大鼠一般状况，在降糖，调节血脂和调节内皮功能方面均具有明显的作用，镜下病理观察试验组动脉粥样硬化程度较模型组减轻，能进一步降低模型大鼠血AGEs水平，升高eNOS水平。
结论:1.本研究结果表明补肾益气活血法有明显的内皮保护和减轻动脉粥样硬化作用，能改善肾虚血瘀型老年2型糖尿病患者的中医临床症状。2.补肾益气活血法改善动脉硬化，改善内皮功能，其作用不仅仅依赖降低血糖，可能通过调节血脂，减少AGEs是生成，调节eNOS活性等多个靶点、多重机制发挥作用。
Objective: To observe the influence of the method of Tonifying the kidney,Supplementing Qi and Activating blood circulation on elderly type2diabetic carotidatherosclerosis and endothelial function, we conduct clinical study and experimental studyto discuss the mechanism on this therapeutic method how to improve the vascularendothelial function and reduce atherosclerosis.
Method:1. Clinical research: Select61patients of eldly type2diabeticarteriosclerosis which both meet the Western diagnosis standard, and simultaneously meetTCM syndrome type of kidney-deficiency and blood stasis, randomly assigned to thecontrol group (30patients) and the test group (31patients).The control group receivedconventional hypoglycemic therapy, the test group also received conventionalhypoglycemic therapy, but add the Chinese medicine decoction based of the method ofTonifying the kidney, Supplementing Qi and Activating blood circulation in addition. After8weeks of treatment, we observed the change of blood glucose, glycosylated hemoglobin,the efficacy of TCM symptoms before and after treatment, and compared the relevantindicators such as hemorheology, endothelin (ET) and nitric oxide (NO), thromboxane B2(TXB2) and6-Keto-prostacyclin (6-Keto-PGF1α), carotid intima-media thickness andarterial plaque area.
Experimental study: Thirty male Wistar rats were randomly divided into3groups, i.e.the blank control group (hereinafter referred to as the blank group), the model controlgroup (hereinafter referred to as the model group) and the experimental group whichreceived the Chinese medicine decoction based of method of Tonifying the kidney,Supplementing Qi and Activating blood circulation (hereinafter referred to as the experimental group), each group had10rats. The latter two groups were fed with the highfat and sugar diet for4weeks to make the experimental modle, After the modeling, theexperimental rats fed with the Chinese medicine decoction based of method of Tonifyingthe kidney, Supplementing Qi and Activating blood circulation for6weeks. After thetreatment, we observed the results including the body weight, blood glucose, blood lipid,and ET, N0,TXB2,6-Keto-PGF1α, AGEs, eNOS of each group, and took the myocardium,aortic pathological sections to observe under the microscope.
Results: The clinical study displayed that the TCM clinical symptoms of the patientsof the test group were improved clearly, and their Fasting glucose,2-hour postprandialblood glucose and glycosylated hemoglobin were reduced than before treatment. Aftertreatment, glycosylated hemoglobin declined clearly in the test group compared with thecontrol group control group. The test group significantly improved endothelial function inpatients, clearly reduced triglycerides, total cholesterol, low-density lipoprotein cholesterollevels, reduced carotid intima-media thickness, and reduced arterial plaque area, theeffects are better than the control group.
Experimental studies have shown that the experimental group drugs can improve thegeneral condition of the type2diabetic rat models, and have a clear role in hypoglycemic,regulation of blood lipid and regulating endothelial functions. Arteriosclerosis situation ofthe experimental group was significantly reduced compared with the model group fromhistological observation. On the other hand, the experimental group drugs can furtherreduce the model rat serum AGEs content and increase eNOS content.
Conclusions:1. The study results show that the method of tonifying the kidney,Supplementing Qi and Activating blood circulation have significant endothelial protectioneffect and can reduce arteriosclerosis, so it can improve the clinical symptoms of thepatients with elderly type2diabetes mellitus which differentiated as kidney-deficiency andblood stasis type.2. The method of tonifying the kidney, Supplementing Qi and Activatingblood circulation can improve arteriosclerosis and enhance endothelial function does notdepend only on lower blood sugar, but also possibly through regulation of blood lipid,reducing the AGEs generating, regulating eNOS activity. These multiple targets, multiplemechanisms play as a role.
方法:1.临床研究选择符合老年2型糖尿病西医诊断标准及中医肾虚血瘀证辨证分型标准，合并有颈动脉粥样斑块形成者61人；随机分对照组（30人）、试验组（31人），对照组予以常规降糖治疗，试验组在此基础上加服补肾益气活血方，治疗8周，观察治疗前后血糖、糖化血红蛋白、中医症候疗效变化，并对血脂、内皮素（ET)和一氧化氮(NO)、血栓素B2(TXB2)和6-酮-前列环素(6-Keto-PGF1α)、颈动脉内膜中层厚度、动脉斑块面积等相关指标进行比较。2.试验研究将WISTAR雄性大鼠随机分为3组，分别为空白组对照组（以下简称空白组）、模型对照组（以下简称模型组）和补肾益气活血方试验组（以下简称试验组），每组各10只。以高脂高糖饲料喂养4周后造模，造模后试验组大鼠灌服补肾益气活血方中药混悬液，连续灌胃6周。6周后观察各组大鼠的体重、血糖、血脂、及ET、N0，TXB2、6-Keto-PGF1α、AGEs、eNOS，并取心肌、主动脉做病理切片进行显微镜下观察。
结果:临床研究显示试验组患者各项中医临床症状改善明显，空腹血糖、餐后2小时血糖和糖化血红蛋白均较治疗前降低，试验组治疗后糖化血红蛋白下降较对照组明显；试验组可显著改善患者内皮功能，疗效优于对照组；试验组可明显降低患者甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平，疗效优于对照组；试验组在降低颈动脉内膜中层厚度，减少颈动脉斑块面积方面优于对照组。
实验研究显示试验组可改善2型糖尿病模型大鼠一般状况，在降糖，调节血脂和调节内皮功能方面均具有明显的作用，镜下病理观察试验组动脉粥样硬化程度较模型组减轻，能进一步降低模型大鼠血AGEs水平，升高eNOS水平。
结论:1.本研究结果表明补肾益气活血法有明显的内皮保护和减轻动脉粥样硬化作用，能改善肾虚血瘀型老年2型糖尿病患者的中医临床症状。2.补肾益气活血法改善动脉硬化，改善内皮功能，其作用不仅仅依赖降低血糖，可能通过调节血脂，减少AGEs是生成，调节eNOS活性等多个靶点、多重机制发挥作用。
Objective: To observe the influence of the method of Tonifying the kidney,Supplementing Qi and Activating blood circulation on elderly type2diabetic carotidatherosclerosis and endothelial function, we conduct clinical study and experimental studyto discuss the mechanism on this therapeutic method how to improve the vascularendothelial function and reduce atherosclerosis.
Method:1. Clinical research: Select61patients of eldly type2diabeticarteriosclerosis which both meet the Western diagnosis standard, and simultaneously meetTCM syndrome type of kidney-deficiency and blood stasis, randomly assigned to thecontrol group (30patients) and the test group (31patients).The control group receivedconventional hypoglycemic therapy, the test group also received conventionalhypoglycemic therapy, but add the Chinese medicine decoction based of the method ofTonifying the kidney, Supplementing Qi and Activating blood circulation in addition. After8weeks of treatment, we observed the change of blood glucose, glycosylated hemoglobin,the efficacy of TCM symptoms before and after treatment, and compared the relevantindicators such as hemorheology, endothelin (ET) and nitric oxide (NO), thromboxane B2(TXB2) and6-Keto-prostacyclin (6-Keto-PGF1α), carotid intima-media thickness andarterial plaque area.
Experimental study: Thirty male Wistar rats were randomly divided into3groups, i.e.the blank control group (hereinafter referred to as the blank group), the model controlgroup (hereinafter referred to as the model group) and the experimental group whichreceived the Chinese medicine decoction based of method of Tonifying the kidney,Supplementing Qi and Activating blood circulation (hereinafter referred to as the experimental group), each group had10rats. The latter two groups were fed with the highfat and sugar diet for4weeks to make the experimental modle, After the modeling, theexperimental rats fed with the Chinese medicine decoction based of method of Tonifyingthe kidney, Supplementing Qi and Activating blood circulation for6weeks. After thetreatment, we observed the results including the body weight, blood glucose, blood lipid,and ET, N0,TXB2,6-Keto-PGF1α, AGEs, eNOS of each group, and took the myocardium,aortic pathological sections to observe under the microscope.
Results: The clinical study displayed that the TCM clinical symptoms of the patientsof the test group were improved clearly, and their Fasting glucose,2-hour postprandialblood glucose and glycosylated hemoglobin were reduced than before treatment. Aftertreatment, glycosylated hemoglobin declined clearly in the test group compared with thecontrol group control group. The test group significantly improved endothelial function inpatients, clearly reduced triglycerides, total cholesterol, low-density lipoprotein cholesterollevels, reduced carotid intima-media thickness, and reduced arterial plaque area, theeffects are better than the control group.
Experimental studies have shown that the experimental group drugs can improve thegeneral condition of the type2diabetic rat models, and have a clear role in hypoglycemic,regulation of blood lipid and regulating endothelial functions. Arteriosclerosis situation ofthe experimental group was significantly reduced compared with the model group fromhistological observation. On the other hand, the experimental group drugs can furtherreduce the model rat serum AGEs content and increase eNOS content.
Conclusions:1. The study results show that the method of tonifying the kidney,Supplementing Qi and Activating blood circulation have significant endothelial protectioneffect and can reduce arteriosclerosis, so it can improve the clinical symptoms of thepatients with elderly type2diabetes mellitus which differentiated as kidney-deficiency andblood stasis type.2. The method of tonifying the kidney, Supplementing Qi and Activatingblood circulation can improve arteriosclerosis and enhance endothelial function does notdepend only on lower blood sugar, but also possibly through regulation of blood lipid,reducing the AGEs generating, regulating eNOS activity. These multiple targets, multiplemechanisms play as a role.
引文
[1]中华医学会糖尿病分会.中国2型糖尿病防治指南(2010年版).中国糖尿病杂志.2012,20(1):S1-S37.
[2]国家中医药管理局.中医病证诊断疗效标准，南京：南京大学出版社，1994，第一版：19.
[3]中华人民共和国卫生部药政司.中药新药临床研究指导原则，第一辑.2002：233-238.
[4]朱文锋，费兆馥，杨牧祥.中医诊断学（第六版），上海：上海科学技术出版社，1995，第一版：164.
[5]中华人民共和国卫生部药政司.新药（中药）治疗老年病的临床研究指导原则.中国医药学报，1989，4（3），72.
[6]高秀娟，马会霞，江春花.2型糖尿病动物模型研究概况.华北煤炭医学院学报，2009，11（6）：783-785.
[7]穆松牛，高云，万福生，等.链尿佐菌素加高糖高脂饮食复制大鼠2型糖尿病模型.中国比较医学杂志，2008，18（2）：19-22.
[8]周迎生，高妍，李斌，等.高脂喂养联合链脉佐菌素注射的糖尿病大鼠模型特征研究报告.中国实验动物学报,2005,13(3):154-158.
[9] Albert Kgm M.The diagnosis and typing for diabetes mellitus[J]. DiabetesVoice1999，44.35.
[10] Yang W，Lu J，Weng J，et al.China National Diabetes and Metabolic Disorders StudyGroup. Prevalence of diabetes among men and women in China[J].N Engl JMed,2010,362(12):1090-1101.
[11]中国2型糖尿病防治指南(2010年版).中国糖尿病杂志，2012，20(1):S2-S3.
[12] Boneti P O, Lerman L O,Lerman A.Endothelial dysfunction, a marker ofatherosclerotic risk[J],Arterioscler Thromb Vasc Biol,2003,23:168-175.
[13] Mourier A,Gautier J F,viler D E,et al.Mobilization of visceral adipose tissue related tothe improvement in insulin sensitivity in response to physical training inNIDDM:effects of branched-chain amino acid supple-ments[J].DiabetesCare,2004,20(14):385-391.
[14] Stevens RJ.Stratton IM,Holman RR,et al,UKPDS58-modeling glucose exposure asarisk factor for photocoagulation in type2diabetes. J DiabetesCompications,2002,16(6):371-376.
[15] Melin R, Hayden,Suresh C.Is type2diabetes mellitus a vacculardisease(atheroscleropathy) with hyperglycemia a late manifestation The role ofNOS,NO and rECDox stress.Cardiovasc Diabetol,2003,2(1):2.
[16] Ceriello A.Hyperglycemia:the bridge bitweennon-enzmatic glycation and oxidativestress in the pathogenisis of diabetic complications.Diabetes NutrMetab,1999;12,:42-46.
[17]王双喜，文格波，曹仁贤，等.葡萄糖对人血管内皮细胞多元醇通路的激活作用及其机理[J].中国动脉硬化杂志，2002,10(3):214一216.
[18] Naruse K,Rask-M C,Takahara N,et al.Activaton of vasular protein kinase C-betainhibits Akt-dependent eddothelial nitric oxide synthase function in besity-associatedinsulin resistance[J]. Diabtes,2006,55(33):691-698.
[19] Chu JW, Abbasi T, Lamendola C, et al. Rosiglitazone enhances insulin sensitivity anddecreases cardiovasular risk factors in insulin-resistant subjects without diabetesmellitus. Diabetes,2002,51:137.
[20]刘智勇，袁兴红，杨永淑.不同期糖尿病肾病血浆一氧化氮、内皮素、氧化低密度脂蛋白水平变化.中华内分泌代谢杂志，2001,17:305.
[21]向光大，何玉生，赵林双，等. T2DM伴血脂异常患者HDL-C与内皮依赖性血管舒张功能的关系[J].中国糖尿病杂志,2007,15(8):474-477.
[22] Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxidesynthase. Metabolism,2000,29:1472-1501.
[23]孙缅恩,杜冠华.晚期糖基化终产物的病理意义及其机制.中国药理学通报.2002Jun;18(3):246-249
[24] Z Makita et al. J-Biol-Chem.1992;267:5133-8.
[25] Takeuchi M, Makita Z, Bucala R et al. Immunological Evidnce thatNon-carboxymethyllysine Advanced Glycation End-puoducts Are Produced fromShort Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine,2000;6(2):114-25.
[26]晚期糖基化终末产物致动脉粥样硬化的机制.蒲里津,陆林,沈卫峰.国际心血管病杂志2006,33(2):98-100.
[27] Thomas MC, Baynes J W,Thorpe SR,et al.The role of AGEs and AGE inhibitors indiabetic cardiovascular disease [J].Curr Drug Targets,2005,6(4):453-474.
[28] Chavakis T, Bierhau A, Nawroth P P. RAGE(receptor for adwancde glycation endproducts): a central player in the inflamatory response [J].MicrobesInfect,2004,6(13):1219-1225.
[29] Hou F F,Reddan D N, Seng W K, et al. Pathogenesis of2-microglobulin amyloidosis:role of monoctds/macrophages[J]. Semin Dial,2001,14:135-139.
[30] Wlassrah, Bucala R, Staiker L, et al. Pathogenic effects of advanced glycosylation:biochemical, biologic, and clinical implications for diabetes and aging[J]. Lab Invest,1994,70:138-151.
[31] Goldin A, Beckman J A, Schimidt A M, et al. Advanced glycation end productssparking the development of diabetic wascular injury[J]. Circulation,2006,114:597-605.
[32] Hanssn G Inflammation, atheroscleosis,and coronary artery diserse.N Engl JMed.2005;325:1685-1695.
[33] Porta M.Selba ML, Molinati P, et al. Endothelial cell function in diabeticmicroangiopathy, Diabealogia,1992,(5):161.
[34] Cooke JP. The endotheliun: a new target for therapy[J].Vase Med,2000,5:49-53.
[35] Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function inthe human cornary and peripheral cirulations[J].J Am CollCardiol,1995,26:1235-1241.
[36] Takase B, Hamabe A, Satomura K, et al.Close relationship between the vasodilatorresponse to acetylcholine in the brachial and coronary artery in suspected coronaryartery disease[J].Intern J Cardiol,2005,105:58-66.
[37] Khan F, Patterson D, Belch JJ,et al. Relationship between peripheral an coronaryfunction using laser Doppler imaging and transthoracic echocardiography[J]. ClinSci(Lond),2008,115:295-300.
[38] Ludmer PL, Selwyn AP, Shook TL, et al. paradoxical vasoconstriction induced byacetylcholine in atherosclerotic coronary arteries. N Engl J Med,1986,345:1046-1051.
[39]. Barth JD. An update on carotidult ra sound mea sure men to fintinamediathickness[J].Am J Card iol,2002,89(suppl):3-39.
[40] Celermajer DS, Sorensen KE. Gooch VM, et al. Non-invasive detection of endothelialdysfunction in children and adults at risk ofatherosclerosis.Lancet,1992,340:1111-1115.
[41]薛莉，史铁梅.超声检测血管内皮功能的研究进展.中国医学影像技术，2006,6（3）：961-964.
[43]程中伟，朱文玲.非对称二甲基一L精氨酸与冠状动脉粥样硬化性心脏病关系的研究进展[J]中华心血管病杂志，2004，32：853-854.
[44]方小正，陈敏，李红，等.波动性高血糖状态与糖尿病微血管病变的研究.医学临床研究.2008,25（11）：1945-1947.
[45] Murate T,Kinoshita K, Hori M,et al. Statin protects endothelial nitric oxide synthaseactivity in hypoxia-induced pulmonary hypertension.Arterioscler Thrmb vascBiol,2005,25:2335-2342.
[46]胡智，刘英明.普伐他汀对2型糖尿病患者血管内皮细胞的保护作用研究田.实用心脑肺血管病杂志，2010,18:113-115.
[47]李风芹，熊辉，刘健群.辛伐他汀对2型糖尿病患者凝血及血管内皮炎性的影响田.中国实用医药，2009,4:9-10.
[48]王珊，江俊麟，贾素洁，等.罗格列酮对糖尿病大鼠血管内皮损伤的保护作用与一氧化氮合酶抑制物的关系[J].中南药学，2005，3:131-135.
[49]楚能武，陈丽，章秋，等.吡格列酮对糖尿病大鼠血管内皮功能的影[J].安徽医药，2009,13:365-367.
[50] Soulis-Liparota T, Gooper ME, Papazoglou D, et al. Diabetes,199140:1328-1334.
[51] Hammes HP, Martin S, Federlin K et al. Proc Natl Acad SciUSA,1991;88:11555-11558.
[52] Kinhara M, Schmeler JD, Poduslo JF et al. Proc Natl Acad Sci USA,1991;6107-6111.
[53] Soulis-Liparota T, Cooper ME, Vranes D et al. Kidney Int,1996;50:627-634.
[54] Wassmann S, Werner N, Czech T, et al. Improwement of endothelial function bysystemic transfusion of vascular progenior cells.Circ Res,2006,99:E74-83.
[55] Li M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1mediatesdiabetes-induced delay in reendothelialzation following arterial injury.CireRes,2006,98:697-704.
[56]陈树春，宋光耀，孙阳，等.初诊2型糖尿病患者外周血内皮祖细胞的研究.天津医药，2010，38（7）：549-551.
[57]郭蕾，李振中，丁学屏，等.糖尿病血管病变的中医病机理论诊释.中华中医药杂志，2009，24（7）：885-888.
[58]梁苹茂，曹克光.2型糖尿病血管并发症中医病机探讨.中医杂志.2006,27(10):726-727.
[59]谢毅强，王华，吴月平，等.2型糖尿病大血管并发症中医证候演变规律探讨.海南医学院学报.2011,17(1):61-63.
[60]陈敏.葛金文.滋阴益气活血方药与2型糖尿病血管并发症的研究进展.湖南中医药大学学报.2008,28(5):79-81.
[61]靳荣光，王秋娟，颜天华，等.红景天昔对H2O2和高糖诱导损伤的血管内皮细胞保护作用研究.中国药理与临床.2012,28(5):41-44.
[62]陈频，徐向进.葛根素治疗2型糖尿病及对凝血纤溶活性和内皮功能的影响日.中国误诊学杂志,2007,7(17):3949-3951.
[63]徐海环，董化江，单娜娜，等.三七总试对糖尿病皮肤溃疡大鼠内皮素-1水平的影响.新乡医学院学报.2012,29(11):815-817.
[64]王丽艳，赵明，银杏叶提取物对糖尿病患者外周血内皮祖细胞GPX及Caspase-3活性的影响.微循环学杂志，2012,22(3):17-20.
[65]贾云，陆付耳，徐丽君，等.小檗碱及8-羟基二氢小檗碱对2型糖尿病大鼠血管内皮功能的影响.中国药学杂志，2010,45(4):273-277.
[66]张海英，王春梅，张明，等.黄连素对2型糖尿病大鼠主动脉内皮功能和形态的影响.吉林大学学报，2010,36（6）：1016-1020.
[67] Gao Q，Qin WS，Jia Z H，et al. Rhein improves renal lesion and amelioratesdyslipidemia in db/db mice with diabetic nephropathy[J].Planta Med，2010，76(1):27-33.
[68]黄金玮，常柏.四妙勇安汤对2型糖尿病大鼠血管内皮细胞功能的影响.天津中医药，2010,27(6):499-500.
[69]徐梓辉，周世文，陈卫，等.薏苡仁多糖对2型糖尿病大鼠主动脉内皮素1基因表达的影响.中国动脉硬化杂志.2006,14(3):194-196.
[70]孙鸿朗，褚伟，陈晓峰,等.中药姜黄对实验性糖尿病大鼠血管病变的影响.湖北中医杂志.2008,30（4）:9-10.
[71]乔进，薛华，孟国梁，等.灵芝多糖对2型糖尿病大鼠胸主动脉内皮功能的保护作用.中国动脉硬化杂志.2009,17(9):709-713.
[72]徐寒松，吴青，谢晓云，等.黄芪多糖对2型糖尿病患者外周血内皮祖细胞增殖及NO生成的影响.山东医药.2011，51(32):26-29.
[73]刘英姿，刘浩然，张坚松.山茱萸总皂首通过调节一氧化氮释放改善链脉佐菌素诱导的糖尿病大鼠肠系膜内皮依赖性舒张.中南大学学报(医学版).2012,37(8):757-764.
[74]王劲松，周玲，成金罗，等.家族高发性2型糖尿病的遗传模遗传式研究[J].2003，25(6):637-640
[75] Thomas F,Balkau B,Vauzelle-Kerwroedan F,et al.Maternal effect and familialaggregaton in NIDDM[J].1994,43(1)63-67.
[76]谭从娥，王米渠，张辉.肾虚证与糖尿病遗传易感性的关联.中医杂志，2011,52（21）：1836-1839.
[77]蒋国彦.实用糖尿病学[M].北京:人民卫生出版社，1992，338.
[78]上海第一医学院实用内科学编辑委员会[M].实用内科学.第17版.北京：人民卫生出版社，1984:889.
[79]胡国俊，胡国堂.健脾运中法治疗老年糖尿病.中国医药学报，1989,4（4）：39-41.
[80]陈和金，王建学.中气虚与糖尿病.中国民间疗法.2011,19（6）：67-68.
[81]张延群，韩清，和贵章，等.2080例糖尿病患者症候与血糖关系分析.中医杂志.1996,37(10):617-620.
[82]魏军平.62例糖尿病患者血液流变学观察.辽宁中医，1993,(8):29.
[83]陈玉碧，郭赛珊，张宏.II型糖尿病患者红细胞SOD、血清LPO水平的观察.北京中医，1995，(4):58-59.
[84]吴晋兰.糖尿病从脾论治初探[J].浙江中医学院学报，1998,22（3）：18.
[85]王福仁，陈波.从脾虚挟湿挟瘀论治2型糖尿病[J].中国中医药信息杂志，2000,7（1）：53.
[86]赵素容，卢兖伟，陈金龙，等.地黄梓醇降糖作用的实验研究.时珍国医国药，2009,20（1）:171-172.
[87]李莉，吴诚，许惠琴，等.药对生地山茱萸抗糖尿病大鼠糖化产物生成的作用研究.辽宁中医药大学学报，2012，14（4）：31-33.
[88] Nocerino E, Amato M, Izzo A A. The aphrodisiac and adaptogenic properties ofginseng[J]. Fitoterapia,2007,71(1):S1-S5.
[89]胡翠华，徐华丽，于晓风，等.人参二醇组皂甙对实验性2型糖尿病大鼠血糖及血脂代谢的影响.2006，32（6）：1004-1008.
[90]张莉，李霞，田建卿.人参、西洋参及其主要活成分的抗糖尿病作用研究进展.药学服务与研究.2009,9(2):122-125.
[91]刘玉莲，杨从忠.黄芪药理作用概述[J].中国药业，2004,13(10):79.
[92]宋淑珍，田亚平，江德清，等.黄芪多糖对健康体检者淋巴细胞亚群的免疫调节作用[J].中国临床康复，2005,9(11):130-131.
[93]高旭，李丽芬，刘斌钰.黄芪多糖对小鼠免疫功能影响的实验研究[J].山西大同大学学报，2010,26(4):43-44.
[94]毛淑梅，李承德，王琳，等.黄芪多糖对糖尿病大鼠胰岛β细胞凋亡作用及机制的研究.中国药理学通报.2009,25(9):1227-9
[95]徐寒松，吴青，谢晓云，等.黄芪多糖对2型糖尿病患者外周血内皮祖细胞PI3K/Akt/eNOS信号通路的影响.2011,15(23):4272-4276.
[96]韩佳，李卫平，栾家杰，等.黄芪总甙对实验性糖尿病小鼠心肌保护作用的研究.安徽医科大学学报.2012,47(3):290-.294.
[97]杨宏莉，张宏馨，李兰会，等.山药多糖对2型糖尿病大鼠HK SDH及MDH活性的影响.辽宁中医药大学学报.2010,12(1):38-39.
[98]张娟，路金才.皂甙的提取方法及含量测定研究进展[J].中国现代中药，2006,8(3):25-28.
[99]徐先祥，李道中，彭代银，等.菟丝子多糖改善糖尿病大鼠糖脂代谢作用.中国实验方剂学杂志，2011，17（18）：232-234.
[100]张培全，谭茵，张超.菟丝子提取物清除自由基作用的研究.中南药学,2012,10(3):171-174.
[101]刘玉平，魏晓东，欧芹，等.菟丝子对D半乳糖致衰老大鼠非酶糖基化及自由基的抑制作用研究.黑龙江医药科学[J]，2006，29(2):1-2.
[102]蔡曦光，许爱霞，葛斌，等.菟丝子多糖抑制衰老小鼠模型中氧自由基域的作用[J].第三军医大学学报，2005，27(13):1326-328.
[103]李静，刘德义.丹参对链脉佐菌糖尿病模型大鼠抗氧化功能的影响.动物医学进展，2010,31(4):30-33.
[104]黄晓磊，王晓东.丹参对糖尿病大鼠肾组织VEGF表达的影响及其保护作用.泰山医学院学报，2011，32（7）：503-506.
[105]向敏，钱之玉，周成华.西红花酸对糖尿病大鼠体内晚期糖基化终产物的形成及其受体表达的影响.中国临床与药理学杂志，2006，11(4):448-452.
[106]韩会民，王树国.葛根素治疗非胰岛素依赖型糖尿病患者胰岛素抵抗的研究.中国中西医结合急救杂志，2006，3(13):117-119.
[107]陆静，刘乃丰，张丽容.葛根素降低糖尿病大鼠血清糖基化终产物水平和单核细胞趋化蛋白一1含量.中华内分泌代谢杂志，2004,20(3):255-258.
[107]杨明炜，赵静，邹欣，等.黄连、生地及其配伍对2型糖尿病大鼠治疗作用的比较研究.中西医结合研究，2012，4（6）：302-305.
[108]安丽萍，王英平，刘晓梅，等.五味子油对链脲佐菌素诱导的2型糖尿病大鼠的影响.中草药，2012,43（3）：552-556.
[109]柴可人，覃志成，王亚丽.北五味子油对糖尿病小鼠抗氧化及葡萄糖转运蛋白4mRNA表达的影响.中医药学刊.2006,24（7）：1199-1201.
[2]国家中医药管理局.中医病证诊断疗效标准，南京：南京大学出版社，1994，第一版：19.
[3]中华人民共和国卫生部药政司.中药新药临床研究指导原则，第一辑.2002：233-238.
[4]朱文锋，费兆馥，杨牧祥.中医诊断学（第六版），上海：上海科学技术出版社，1995，第一版：164.
[5]中华人民共和国卫生部药政司.新药（中药）治疗老年病的临床研究指导原则.中国医药学报，1989，4（3），72.
[6]高秀娟，马会霞，江春花.2型糖尿病动物模型研究概况.华北煤炭医学院学报，2009，11（6）：783-785.
[7]穆松牛，高云，万福生，等.链尿佐菌素加高糖高脂饮食复制大鼠2型糖尿病模型.中国比较医学杂志，2008，18（2）：19-22.
[8]周迎生，高妍，李斌，等.高脂喂养联合链脉佐菌素注射的糖尿病大鼠模型特征研究报告.中国实验动物学报,2005,13(3):154-158.
[9] Albert Kgm M.The diagnosis and typing for diabetes mellitus[J]. DiabetesVoice1999，44.35.
[10] Yang W，Lu J，Weng J，et al.China National Diabetes and Metabolic Disorders StudyGroup. Prevalence of diabetes among men and women in China[J].N Engl JMed,2010,362(12):1090-1101.
[11]中国2型糖尿病防治指南(2010年版).中国糖尿病杂志，2012，20(1):S2-S3.
[12] Boneti P O, Lerman L O,Lerman A.Endothelial dysfunction, a marker ofatherosclerotic risk[J],Arterioscler Thromb Vasc Biol,2003,23:168-175.
[13] Mourier A,Gautier J F,viler D E,et al.Mobilization of visceral adipose tissue related tothe improvement in insulin sensitivity in response to physical training inNIDDM:effects of branched-chain amino acid supple-ments[J].DiabetesCare,2004,20(14):385-391.
[14] Stevens RJ.Stratton IM,Holman RR,et al,UKPDS58-modeling glucose exposure asarisk factor for photocoagulation in type2diabetes. J DiabetesCompications,2002,16(6):371-376.
[15] Melin R, Hayden,Suresh C.Is type2diabetes mellitus a vacculardisease(atheroscleropathy) with hyperglycemia a late manifestation The role ofNOS,NO and rECDox stress.Cardiovasc Diabetol,2003,2(1):2.
[16] Ceriello A.Hyperglycemia:the bridge bitweennon-enzmatic glycation and oxidativestress in the pathogenisis of diabetic complications.Diabetes NutrMetab,1999;12,:42-46.
[17]王双喜，文格波，曹仁贤，等.葡萄糖对人血管内皮细胞多元醇通路的激活作用及其机理[J].中国动脉硬化杂志，2002,10(3):214一216.
[18] Naruse K,Rask-M C,Takahara N,et al.Activaton of vasular protein kinase C-betainhibits Akt-dependent eddothelial nitric oxide synthase function in besity-associatedinsulin resistance[J]. Diabtes,2006,55(33):691-698.
[19] Chu JW, Abbasi T, Lamendola C, et al. Rosiglitazone enhances insulin sensitivity anddecreases cardiovasular risk factors in insulin-resistant subjects without diabetesmellitus. Diabetes,2002,51:137.
[20]刘智勇，袁兴红，杨永淑.不同期糖尿病肾病血浆一氧化氮、内皮素、氧化低密度脂蛋白水平变化.中华内分泌代谢杂志，2001,17:305.
[21]向光大，何玉生，赵林双，等. T2DM伴血脂异常患者HDL-C与内皮依赖性血管舒张功能的关系[J].中国糖尿病杂志,2007,15(8):474-477.
[22] Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxidesynthase. Metabolism,2000,29:1472-1501.
[23]孙缅恩,杜冠华.晚期糖基化终产物的病理意义及其机制.中国药理学通报.2002Jun;18(3):246-249
[24] Z Makita et al. J-Biol-Chem.1992;267:5133-8.
[25] Takeuchi M, Makita Z, Bucala R et al. Immunological Evidnce thatNon-carboxymethyllysine Advanced Glycation End-puoducts Are Produced fromShort Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine,2000;6(2):114-25.
[26]晚期糖基化终末产物致动脉粥样硬化的机制.蒲里津,陆林,沈卫峰.国际心血管病杂志2006,33(2):98-100.
[27] Thomas MC, Baynes J W,Thorpe SR,et al.The role of AGEs and AGE inhibitors indiabetic cardiovascular disease [J].Curr Drug Targets,2005,6(4):453-474.
[28] Chavakis T, Bierhau A, Nawroth P P. RAGE(receptor for adwancde glycation endproducts): a central player in the inflamatory response [J].MicrobesInfect,2004,6(13):1219-1225.
[29] Hou F F,Reddan D N, Seng W K, et al. Pathogenesis of2-microglobulin amyloidosis:role of monoctds/macrophages[J]. Semin Dial,2001,14:135-139.
[30] Wlassrah, Bucala R, Staiker L, et al. Pathogenic effects of advanced glycosylation:biochemical, biologic, and clinical implications for diabetes and aging[J]. Lab Invest,1994,70:138-151.
[31] Goldin A, Beckman J A, Schimidt A M, et al. Advanced glycation end productssparking the development of diabetic wascular injury[J]. Circulation,2006,114:597-605.
[32] Hanssn G Inflammation, atheroscleosis,and coronary artery diserse.N Engl JMed.2005;325:1685-1695.
[33] Porta M.Selba ML, Molinati P, et al. Endothelial cell function in diabeticmicroangiopathy, Diabealogia,1992,(5):161.
[34] Cooke JP. The endotheliun: a new target for therapy[J].Vase Med,2000,5:49-53.
[35] Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function inthe human cornary and peripheral cirulations[J].J Am CollCardiol,1995,26:1235-1241.
[36] Takase B, Hamabe A, Satomura K, et al.Close relationship between the vasodilatorresponse to acetylcholine in the brachial and coronary artery in suspected coronaryartery disease[J].Intern J Cardiol,2005,105:58-66.
[37] Khan F, Patterson D, Belch JJ,et al. Relationship between peripheral an coronaryfunction using laser Doppler imaging and transthoracic echocardiography[J]. ClinSci(Lond),2008,115:295-300.
[38] Ludmer PL, Selwyn AP, Shook TL, et al. paradoxical vasoconstriction induced byacetylcholine in atherosclerotic coronary arteries. N Engl J Med,1986,345:1046-1051.
[39]. Barth JD. An update on carotidult ra sound mea sure men to fintinamediathickness[J].Am J Card iol,2002,89(suppl):3-39.
[40] Celermajer DS, Sorensen KE. Gooch VM, et al. Non-invasive detection of endothelialdysfunction in children and adults at risk ofatherosclerosis.Lancet,1992,340:1111-1115.
[41]薛莉，史铁梅.超声检测血管内皮功能的研究进展.中国医学影像技术，2006,6（3）：961-964.
[43]程中伟，朱文玲.非对称二甲基一L精氨酸与冠状动脉粥样硬化性心脏病关系的研究进展[J]中华心血管病杂志，2004，32：853-854.
[44]方小正，陈敏，李红，等.波动性高血糖状态与糖尿病微血管病变的研究.医学临床研究.2008,25（11）：1945-1947.
[45] Murate T,Kinoshita K, Hori M,et al. Statin protects endothelial nitric oxide synthaseactivity in hypoxia-induced pulmonary hypertension.Arterioscler Thrmb vascBiol,2005,25:2335-2342.
[46]胡智，刘英明.普伐他汀对2型糖尿病患者血管内皮细胞的保护作用研究田.实用心脑肺血管病杂志，2010,18:113-115.
[47]李风芹，熊辉，刘健群.辛伐他汀对2型糖尿病患者凝血及血管内皮炎性的影响田.中国实用医药，2009,4:9-10.
[48]王珊，江俊麟，贾素洁，等.罗格列酮对糖尿病大鼠血管内皮损伤的保护作用与一氧化氮合酶抑制物的关系[J].中南药学，2005，3:131-135.
[49]楚能武，陈丽，章秋，等.吡格列酮对糖尿病大鼠血管内皮功能的影[J].安徽医药，2009,13:365-367.
[50] Soulis-Liparota T, Gooper ME, Papazoglou D, et al. Diabetes,199140:1328-1334.
[51] Hammes HP, Martin S, Federlin K et al. Proc Natl Acad SciUSA,1991;88:11555-11558.
[52] Kinhara M, Schmeler JD, Poduslo JF et al. Proc Natl Acad Sci USA,1991;6107-6111.
[53] Soulis-Liparota T, Cooper ME, Vranes D et al. Kidney Int,1996;50:627-634.
[54] Wassmann S, Werner N, Czech T, et al. Improwement of endothelial function bysystemic transfusion of vascular progenior cells.Circ Res,2006,99:E74-83.
[55] Li M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1mediatesdiabetes-induced delay in reendothelialzation following arterial injury.CireRes,2006,98:697-704.
[56]陈树春，宋光耀，孙阳，等.初诊2型糖尿病患者外周血内皮祖细胞的研究.天津医药，2010，38（7）：549-551.
[57]郭蕾，李振中，丁学屏，等.糖尿病血管病变的中医病机理论诊释.中华中医药杂志，2009，24（7）：885-888.
[58]梁苹茂，曹克光.2型糖尿病血管并发症中医病机探讨.中医杂志.2006,27(10):726-727.
[59]谢毅强，王华，吴月平，等.2型糖尿病大血管并发症中医证候演变规律探讨.海南医学院学报.2011,17(1):61-63.
[60]陈敏.葛金文.滋阴益气活血方药与2型糖尿病血管并发症的研究进展.湖南中医药大学学报.2008,28(5):79-81.
[61]靳荣光，王秋娟，颜天华，等.红景天昔对H2O2和高糖诱导损伤的血管内皮细胞保护作用研究.中国药理与临床.2012,28(5):41-44.
[62]陈频，徐向进.葛根素治疗2型糖尿病及对凝血纤溶活性和内皮功能的影响日.中国误诊学杂志,2007,7(17):3949-3951.
[63]徐海环，董化江，单娜娜，等.三七总试对糖尿病皮肤溃疡大鼠内皮素-1水平的影响.新乡医学院学报.2012,29(11):815-817.
[64]王丽艳，赵明，银杏叶提取物对糖尿病患者外周血内皮祖细胞GPX及Caspase-3活性的影响.微循环学杂志，2012,22(3):17-20.
[65]贾云，陆付耳，徐丽君，等.小檗碱及8-羟基二氢小檗碱对2型糖尿病大鼠血管内皮功能的影响.中国药学杂志，2010,45(4):273-277.
[66]张海英，王春梅，张明，等.黄连素对2型糖尿病大鼠主动脉内皮功能和形态的影响.吉林大学学报，2010,36（6）：1016-1020.
[67] Gao Q，Qin WS，Jia Z H，et al. Rhein improves renal lesion and amelioratesdyslipidemia in db/db mice with diabetic nephropathy[J].Planta Med，2010，76(1):27-33.
[68]黄金玮，常柏.四妙勇安汤对2型糖尿病大鼠血管内皮细胞功能的影响.天津中医药，2010,27(6):499-500.
[69]徐梓辉，周世文，陈卫，等.薏苡仁多糖对2型糖尿病大鼠主动脉内皮素1基因表达的影响.中国动脉硬化杂志.2006,14(3):194-196.
[70]孙鸿朗，褚伟，陈晓峰,等.中药姜黄对实验性糖尿病大鼠血管病变的影响.湖北中医杂志.2008,30（4）:9-10.
[71]乔进，薛华，孟国梁，等.灵芝多糖对2型糖尿病大鼠胸主动脉内皮功能的保护作用.中国动脉硬化杂志.2009,17(9):709-713.
[72]徐寒松，吴青，谢晓云，等.黄芪多糖对2型糖尿病患者外周血内皮祖细胞增殖及NO生成的影响.山东医药.2011，51(32):26-29.
[73]刘英姿，刘浩然，张坚松.山茱萸总皂首通过调节一氧化氮释放改善链脉佐菌素诱导的糖尿病大鼠肠系膜内皮依赖性舒张.中南大学学报(医学版).2012,37(8):757-764.
[74]王劲松，周玲，成金罗，等.家族高发性2型糖尿病的遗传模遗传式研究[J].2003，25(6):637-640
[75] Thomas F,Balkau B,Vauzelle-Kerwroedan F,et al.Maternal effect and familialaggregaton in NIDDM[J].1994,43(1)63-67.
[76]谭从娥，王米渠，张辉.肾虚证与糖尿病遗传易感性的关联.中医杂志，2011,52（21）：1836-1839.
[77]蒋国彦.实用糖尿病学[M].北京:人民卫生出版社，1992，338.
[78]上海第一医学院实用内科学编辑委员会[M].实用内科学.第17版.北京：人民卫生出版社，1984:889.
[79]胡国俊，胡国堂.健脾运中法治疗老年糖尿病.中国医药学报，1989,4（4）：39-41.
[80]陈和金，王建学.中气虚与糖尿病.中国民间疗法.2011,19（6）：67-68.
[81]张延群，韩清，和贵章，等.2080例糖尿病患者症候与血糖关系分析.中医杂志.1996,37(10):617-620.
[82]魏军平.62例糖尿病患者血液流变学观察.辽宁中医，1993,(8):29.
[83]陈玉碧，郭赛珊，张宏.II型糖尿病患者红细胞SOD、血清LPO水平的观察.北京中医，1995，(4):58-59.
[84]吴晋兰.糖尿病从脾论治初探[J].浙江中医学院学报，1998,22（3）：18.
[85]王福仁，陈波.从脾虚挟湿挟瘀论治2型糖尿病[J].中国中医药信息杂志，2000,7（1）：53.
[86]赵素容，卢兖伟，陈金龙，等.地黄梓醇降糖作用的实验研究.时珍国医国药，2009,20（1）:171-172.
[87]李莉，吴诚，许惠琴，等.药对生地山茱萸抗糖尿病大鼠糖化产物生成的作用研究.辽宁中医药大学学报，2012，14（4）：31-33.
[88] Nocerino E, Amato M, Izzo A A. The aphrodisiac and adaptogenic properties ofginseng[J]. Fitoterapia,2007,71(1):S1-S5.
[89]胡翠华，徐华丽，于晓风，等.人参二醇组皂甙对实验性2型糖尿病大鼠血糖及血脂代谢的影响.2006，32（6）：1004-1008.
[90]张莉，李霞，田建卿.人参、西洋参及其主要活成分的抗糖尿病作用研究进展.药学服务与研究.2009,9(2):122-125.
[91]刘玉莲，杨从忠.黄芪药理作用概述[J].中国药业，2004,13(10):79.
[92]宋淑珍，田亚平，江德清，等.黄芪多糖对健康体检者淋巴细胞亚群的免疫调节作用[J].中国临床康复，2005,9(11):130-131.
[93]高旭，李丽芬，刘斌钰.黄芪多糖对小鼠免疫功能影响的实验研究[J].山西大同大学学报，2010,26(4):43-44.
[94]毛淑梅，李承德，王琳，等.黄芪多糖对糖尿病大鼠胰岛β细胞凋亡作用及机制的研究.中国药理学通报.2009,25(9):1227-9
[95]徐寒松，吴青，谢晓云，等.黄芪多糖对2型糖尿病患者外周血内皮祖细胞PI3K/Akt/eNOS信号通路的影响.2011,15(23):4272-4276.
[96]韩佳，李卫平，栾家杰，等.黄芪总甙对实验性糖尿病小鼠心肌保护作用的研究.安徽医科大学学报.2012,47(3):290-.294.
[97]杨宏莉，张宏馨，李兰会，等.山药多糖对2型糖尿病大鼠HK SDH及MDH活性的影响.辽宁中医药大学学报.2010,12(1):38-39.
[98]张娟，路金才.皂甙的提取方法及含量测定研究进展[J].中国现代中药，2006,8(3):25-28.
[99]徐先祥，李道中，彭代银，等.菟丝子多糖改善糖尿病大鼠糖脂代谢作用.中国实验方剂学杂志，2011，17（18）：232-234.
[100]张培全，谭茵，张超.菟丝子提取物清除自由基作用的研究.中南药学,2012,10(3):171-174.
[101]刘玉平，魏晓东，欧芹，等.菟丝子对D半乳糖致衰老大鼠非酶糖基化及自由基的抑制作用研究.黑龙江医药科学[J]，2006，29(2):1-2.
[102]蔡曦光，许爱霞，葛斌，等.菟丝子多糖抑制衰老小鼠模型中氧自由基域的作用[J].第三军医大学学报，2005，27(13):1326-328.
[103]李静，刘德义.丹参对链脉佐菌糖尿病模型大鼠抗氧化功能的影响.动物医学进展，2010,31(4):30-33.
[104]黄晓磊，王晓东.丹参对糖尿病大鼠肾组织VEGF表达的影响及其保护作用.泰山医学院学报，2011，32（7）：503-506.
[105]向敏，钱之玉，周成华.西红花酸对糖尿病大鼠体内晚期糖基化终产物的形成及其受体表达的影响.中国临床与药理学杂志，2006，11(4):448-452.
[106]韩会民，王树国.葛根素治疗非胰岛素依赖型糖尿病患者胰岛素抵抗的研究.中国中西医结合急救杂志，2006，3(13):117-119.
[107]陆静，刘乃丰，张丽容.葛根素降低糖尿病大鼠血清糖基化终产物水平和单核细胞趋化蛋白一1含量.中华内分泌代谢杂志，2004,20(3):255-258.
[107]杨明炜，赵静，邹欣，等.黄连、生地及其配伍对2型糖尿病大鼠治疗作用的比较研究.中西医结合研究，2012，4（6）：302-305.
[108]安丽萍，王英平，刘晓梅，等.五味子油对链脲佐菌素诱导的2型糖尿病大鼠的影响.中草药，2012,43（3）：552-556.
[109]柴可人，覃志成，王亚丽.北五味子油对糖尿病小鼠抗氧化及葡萄糖转运蛋白4mRNA表达的影响.中医药学刊.2006,24（7）：1199-1201.